Case Studies
Client Situation
The objective was to increase market share of target prescribers through an AI-powered Next Best Action model
Trinity’s Role
We were able to deploy this solution in 3 weeks. The project included:
Discussions with the client team to finalize standardized business rules for brand-agnostic data and KPI definitions
Master dataset development through applying business rules and automated monthly PySpark code refreshes
State-of-the-art machine learning algorithms like reinforcement learning, deep neural networks with dynamic recalibration and automated hyperparameter tuning…
Read Now
Webinars
Available On Demand
Did you know 62% of products launched between September 2019 and December 2021 underperformed expectations in the first year of launch?
What is going wrong, and how can we get it right? Join Trinity Life Sciences for a thought-provoking webinar to dive into the first white paper in our Industry Impact Series, Picking Winners: Portfolio Management for a New Era.
Hear from Trinity’s Leslie Orne, President & CEO, Herman Sanchez, Chief Business Officer and Chad Faulkner, Partner, as they explore the challenges…
Watch Now
Blog
Published April 22, 2024
Executive Summary
The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system.
The 2024 PLFSS emphasizes:
Drug access and cost containment, with a higher payback trigger aimed at reducing the government’s payback collections
Temporary reimbursement to ensure continuous treatment of patients with medicines benefitting from the early…
Read Now
Scientific Publications
Healthcare Resource Utilization of Patients with Short Bowel Syndrome Dependent on Parenteral Support: A Retrospective Claims Analysis
AUTHOR(S): Ali A1, Micic D2, Gallivan M1, Kulkarni A3, Henderson J4, Mitchell G4 1Trinity Life Sciences, Waltham, MA, USA, 2University of Chicago Medical Center, Gastroenterology, Hepatology, and Nutrition, Chicago, IL, USA, 3Trinity Life Sciences, Malden, MA, USA, 4VectivBio AG, Basel, Basel, Switzerland
OBJECTIVES: Short bowel syndrome with intestinal failure (SBS-IF) is a rare, chronic, debilitating malabsorptive condition often caused by massive resection of the…
Read Now
Webinars
Available On Demand
Generative AI (GenAI) has created an opportunity to re-think and significantly improve how we work. Although far from replacing humans, GenAI has the potential to make pharma professionals far more effective and valuable to their organizations. Join us for “Making AI Real,” a webinar series from Trinity Life Sciences dedicated to exploring how to leverage generative AI across different areas within pharmaceutical commercial operations and medical affairs. Our first webinar in this series will be on AI for Insights: discover how generative AI…
Watch Now
Webinars
Available On Demand
How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL?
As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for manufacturers aiming to achieve successful access and pricing outcomes.
In this webinar, a panel of Trinity Life Sciences’ Value, Access and Pricing experts will discuss the role of the new value-based assessment framework in NRDL payer decision-making and dive…
Watch Now
White Papers
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they deploy it to better support their innovative medicines at launch and beyond.
Complete the form below to access the full white paper
By submitting this…
Read Now
Blog
Published April 5, 2024
Executive Summary
Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into the new Canadian Drug Agency (CDA) over the course of the next five years, as well as the implementation of time-limited reimbursement for specific drugs.
While the Canadian Drug Agency is set to advance Canada’s pharmaceutical system by standardizing…
Read Now
Blog
Published April 5, 2024
Executive Summary
“Transparency in Coverage” (TIC) data is a newer data source that has recently become available for mining unique insights in the reimbursement/economics between payers and providers. In 2020, the Federal Government TIC Rule required health insurers and group health plans, including self-funded clients, to provide cost-sharing data to consumers via machine-readable files and a consumer price transparency tool. Beginning July 1, 2022, machine-readable files were published publicly, and include pricing data for covered items and services based on…
Read Now
White Papers
The biopharmaceutical industry is known for its promise of life-changing innovations, but many companies continue to advance the wrong therapies into the clinic, resulting in underperformance and wasted resources. This white paper explores the concentration of activity on well-trodden ground, and the lack of focus on true innovation. With increasing global pricing pressures and policy changes, it is more important than ever to be selective about the drugs that are advanced into the market. This white paper offers insights and…
Read Now
